相关事项的独立意见 北大医药股份有限公司（以下简称"公司"）第十届董事会第十一次会议于 2023 年 8 月 23 日上午 10:00 在重庆市渝北区金开大道 56 号两江天地 1 单元 10 楼会议室以现场结合通讯方式召开。根据《深圳证券交易所股票上市规则》、《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》、《上 市公司独立董事规则》、《公司章程》及有关法律法规规定，我们作为公司的独 立董事，基于独立判断的立场，在认真审阅有关资料和充分沟通的基础上，就公 司第十届董事会第十一次会议审议的有关事项发表如下独立意见： 北大医药股份有限公司 独立董事关于公司第十届董事会第十一次会议 一、关于补选公司第十届董事会非独立董事的独立意见 北大医药股份有限公司 独立董事：曾建光、靳景玉、陶剑虹 二〇二三年八月二十三日 我们认为，本次公司提名非独立董事程序符合《公司法》《公司章程》的有 关规定，不存在损害公司及其他股东利益的情形。我们同意《关于补选公司第十 届董事会非独立董事的议案》，并同意将该议案提交公司股东大会议审议。 二、关于公司 2023 年半年度计提资产减值准备的独立意见 本次计提资产减 ...

关于公司2023年半年度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为了更加真实、准确地反映北大医药股份有限公司（以下简称"公司"）截 止 2023 年 06 月 30 日的资产和财务状况，根据《企业会计准则》及《深圳证券 交易所股票上市规则》的规定，公司基于谨慎性原则，对合并范围内截至 2023 年 6 月 30 日应收款项、存货、固定资产、开发支出、无形资产等有关资产的减 值情况进行了清理，有关清理情况及拟计提减值准备情况如下： 一、本次计提资产减值准备的资产范围、总金额 根据《企业会计准则》和公司会计政策的相关要求，结合公司运营实际，本 着谨慎性原则，经过对公司合并范围内截至 2023 年 6 月 30 日可能存在发生减值 迹象的资产进行全面清查并对有关资产减值测试后，2023 年半年度报告期计提 1,042.51 万元，本期转销 773.70 万元，本期核销 804.92 万元，本次计提资产 减值准备的相关数据未经审计，最终以会计师事务所审计的财务数据为准。本次 计提资产减值准备具体情况如下： 证券代码：000788 证券简 ...

经审核，公司监事会认为，公司本次计提资产减值准备的决议程序合法，依 据充分；计提符合《企业会计准则》等相关规定，符合公司实际情况，计提后更 能公允反映公司财务状况和经营成果，不存在损害公司和全体股东特别是中小股 东利益的情况。 北大医药股份有限公司 监事会审核意见 北大医药股份有限公司（以下简称"公司"）第十届监事会第十次会议于 2023 年 8 月 23 日上午 11:00 在重庆市渝北区金开大道 56 号两江天地 1 单元 10 楼会议室以现场结合通讯方式召开。根据《深圳证券交易所股票上市规则》、《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》和《公 司章程》及有关法律法规规定，就以下事项发表如下审核意见： 1、《2023 年半年度报告全文及摘要》的审核意见 经审核，公司监事会认为，董事会编制和审核公司 2023 年半年度报告的程 序符合法律、行政法规和中国证监会的相关规定，报告内容真实、准确、完整地 反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 2、《关于公司 2023 年半年度计提资产减值准备的议案》的审核意见 北大医药股份有限公司 监 事 会 二〇二三 ...

3、报告期内，公司为全资子公司提供的担保发生额为 0.34 亿元，占公司当 期归母净资产的 2.42%；子公司之间未发生相互担保。 4、报告期内，公司严格控制对外担保的风险，担保行为履行了相关的审批 程序，符合有关政策法规和公司章程的规定，不会损害公司及股东的利益，尤其 是中小股东的利益。 北大医药股份有限公司 独立董事：曾建光、靳景玉、陶剑虹 二〇二三年八月二十三日 北大医药股份有限公司（以下简称"公司"）第十届董事会第十一次会议于 2023 年 8 月 23 日上午 10:00 在重庆市渝北区金开大道 56 号两江天地 1 单元 10 楼会议室以现场结合通讯方式召开。根据《深圳证券交易所股票上市规则》、《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》、《上 市公司独立董事规则》、《上市公司监管指引第 8 号——上市公司资金往来、对 外担保的监管要求》等法律法规的规定，我们作为公司的独立董事，本着实事求 是的态度，对公司报告期内发生或以前期间发生但延续到报告期的控股股东及其 他关联方占用公司资金、公司对外担保情况等进行了专项检查，基于客观、独立 判断立场，现就上述情况发表如下专项说 ...

证券代码：000788 证券简称：北大医药 公告编号：2023-031 北大医药股份有限公司 关于持股5%以上股东被动减持计划实施进展 暨减持数量过半的公告 股东西南合成医药集团有限公司保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 1．股东被动减持股份情况 | 被动减持股 | 股东 | 减持 | 被动减持股数 | 减持股份 | 被动减持方式 | 减持期间 | 数占公司总 | 名称 | 均价（元/股） | （股） | 来源 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股本比例（%） | 西南 | 首次公开 | | | | | | | | | | | 合成 | 集中竞价交易 | 2023.8.14-2023.8.15 | 6.91 | 3,935,341 | 0.66% | 发行股票 | 医药 | 并上市前 | | | | | 集团 | 持有的股 | 有限 | 合 计 ...

证券代码：000788 证券简称：北大医药 公告编号：2023-030 北大医药股份有限公司 关于持股5%以上股东被动减持计划时间届满暨 被动减持计划实施完毕及所持部分股票被轮候冻结、 部分冻结股票面临被执行处置风险的公告 股东西南合成医药集团有限公司保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北大医药股份有限公司（以下简称"上市公司"）于 2023 年 4 月 18 日披露 了《关于持股 5%以上股东所持部分股份被轮候冻结及被动减持的预披露公告》 （公告编号：2023-006），股东西南合成医药集团有限公司（以下简称"合成集 团"）应中泰证券股份有限公司（以下简称"中泰证券"）的要求及融资合约约 定，将在被动减持计划公告披露之日起 15 个交易日后的 3 个月内进行减持。被 动减持将遵守上市公司股东减持股份的相关法律规定：采用集中竞价交易方式减 持的，在任意连续九十个自然日内，减持股份的总数不得超过上市公司股份总数 的 1%；采用大宗交易方式减持的，在任意连续九十个自然日 ...

Financial Performance - The company reported a total revenue of CNY 1.5 billion for the year 2022, representing a year-on-year increase of 10%[19]. - The net profit attributable to shareholders was CNY 300 million, which is a 15% increase compared to the previous year[19]. - The company's operating revenue for 2022 was ¥2,077,355,184.20, a decrease of 7.13% compared to ¥2,236,776,376.12 in 2021[25]. - The net profit attributable to shareholders for 2022 was ¥55,981,935.11, representing a 29.76% increase from ¥43,143,838.36 in 2021[25]. - The gross profit margin for the pharmaceutical manufacturing sector was 79.73%, while the pharmaceutical distribution sector had a gross profit margin of 12.07%[65]. - The company achieved operating revenue of 2.077 billion yuan, a decrease of 7.13% compared to the previous year[47]. - The company reported a total revenue for 2022 of ¥2,077,355,184.20, representing a decrease of 7.13% compared to ¥2,236,776,376.12 in 2021[63]. - The pharmaceutical manufacturing sector contributed ¥770,700,824.90, accounting for 37.10% of total revenue, down 12.76% from the previous year[63]. - The pharmaceutical distribution sector generated ¥1,306,654,359.30, making up 62.90% of total revenue, with a decrease of 3.45% year-on-year[63]. User Growth and Market Expansion - User data showed an increase in active users by 20%, reaching a total of 1 million active users by the end of 2022[19]. - The company plans to launch three new products in 2023, focusing on innovative drug delivery systems[19]. - Market expansion efforts include entering two new provinces, aiming for a 25% increase in market share in those regions[19]. - User data showed a 15% increase in active users, reaching 2 million by the end of the reporting period[116]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[116]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[123]. Research and Development - The company has allocated CNY 200 million for research and development in new technologies for the upcoming fiscal year[19]. - The company has a dedicated R&D center with a complete organizational structure and approximately 10,000 square meters of pilot and pilot test bases[49]. - The R&D model includes both independent development and collaborative research, forming a rich pipeline of products under development[49]. - The total R&D investment for 2022 was ¥28,248,468.31, a decrease of 33.81% compared to ¥42,677,839.70 in 2021[77]. - The proportion of R&D investment to operating revenue was 1.36%, down from 1.91% in the previous year, reflecting a decrease of 0.55%[77]. - The R&D expenditure for new products and technologies increased by 20% year-on-year, indicating a strong commitment to innovation[123]. - The company introduced 49 new talents focused on R&D, quality, and production, enhancing its operational capabilities[59]. - The company plans to focus on three core areas: anti-infection, analgesics, and psychiatric drugs, aiming to enhance product offerings through both internal development and external collaborations[97]. Strategic Initiatives and Acquisitions - A strategic acquisition of a smaller biotech firm was completed, expected to enhance the company's product pipeline and capabilities[19]. - A strategic acquisition of a local pharmaceutical company is expected to enhance the company's product portfolio and distribution network[117]. - The company has established an industrial merger and acquisition fund with a total committed capital of CNY 500 million to CNY 700 million, with a 30% stake in the fund management company[182]. Operational Efficiency and Cost Management - The company has set a target to reduce operational costs by 15% over the next year through efficiency improvements[116]. - The company actively adjusted its product structure and improved management efficiency to achieve a nearly 30% increase in net profit despite the revenue decline[53]. - The company is committed to optimizing its pharmaceutical business while focusing on the industrial sector, aiming for "value maximization" in its operations[52]. Corporate Governance and Compliance - The company has a board of directors consisting of 8 members, including 3 independent directors, complying with legal and regulatory requirements[109]. - The company emphasizes information disclosure, ensuring timely and accurate information is available to all shareholders through designated media[110]. - The company has established an effective internal control system in compliance with relevant laws and regulations, ensuring risk identification and management[140]. - The internal control self-evaluation report indicated that there were no significant defects in financial reporting or non-financial reporting during the reporting period[142]. - The company has committed to maintaining an independent financial structure, including separate bank accounts and financial decision-making processes[161]. Social Responsibility and Community Engagement - The company maintains a robust investor relations management system, including hosting annual performance briefings and participating in investor reception activities[148]. - The company actively fulfills its social responsibilities, ensuring the protection of shareholders, employees, and customers' rights while adhering to sustainable development principles[148]. - The company has engaged in charitable activities to support rural infrastructure and improve living conditions, demonstrating its commitment to social responsibility[151]. - The company has committed to enhancing environmental protection by investing in projects such as wastewater treatment facilities, ensuring compliance with national standards[149]. Challenges and Risks - The management highlighted potential risks including regulatory changes and market competition, with strategies in place to mitigate these risks[4]. - The company faces ongoing challenges in cost control due to rising labor and raw material costs, alongside depreciation expenses[36]. - The company faces risks from industry policy changes, including drug approval and pricing pressures, and will enhance product quality and R&D speed to adapt[100]. - Rising raw material prices and drug price reductions pose risks, prompting the company to boost market promotion and explore mergers and acquisitions[101].

Financial Performance - The company's operating revenue for Q1 2023 was ¥498,709,845.17, representing a 3.46% increase compared to ¥482,036,482.63 in the same period last year[5] - Net profit attributable to shareholders for Q1 2023 was ¥16,705,869.02, a significant increase of 40.71% from ¥11,872,378.05 in Q1 2022[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥16,960,415.93, reflecting a 40.74% increase year-on-year[5] - Basic and diluted earnings per share for Q1 2023 were both ¥0.0280, up 40.70% from ¥0.0199 in Q1 2022[5] - Operating profit for Q1 2023 reached CNY 21,621,826.38, compared to CNY 14,565,050.34 in the previous year, indicating a growth of 48.3%[22] - The net profit for the first quarter of 2023 was CNY 16,693,448.90, representing an increase of 40.5% compared to CNY 11,871,474.86 in the same period last year[24] - The company reported a total profit of CNY 20,942,175.12, which is an increase from CNY 14,050,032.57 year-over-year[24] Cash Flow and Assets - The net cash flow from operating activities was -¥130,571,632.68, a drastic decline of 3,266.62% compared to -¥3,878,417.69 in the previous year[5] - The company's cash and cash equivalents decreased by 41.20% to ¥372,524,823.30, primarily due to reduced cash collections and loan repayments[9] - Cash and cash equivalents decreased to CNY 372,524,823.30 from CNY 633,520,126.20 at the beginning of the year, a decline of 41.1%[20] - Total assets at the end of Q1 2023 were ¥2,457,157,151.47, down 6.83% from ¥2,636,633,493.03 at the end of the previous year[5] - Total assets decreased to CNY 2,457,157,151.47 from CNY 2,637,335,665.00, a reduction of 6.8%[21] - The total cash flow from operating activities was negative CNY 130,571,632.68, a significant decline from negative CNY 3,878,417.69 in the prior year[25] - The cash flow from investing activities was negative CNY 10,790,722.65, compared to negative CNY 2,058,938.77 in the previous year, indicating increased investment outflows[26] - The cash flow from financing activities was negative CNY 142,010,858.86, a significant increase from negative CNY 9,133,912.37 in the prior year[26] Shareholder Information - The total number of common shareholders at the end of the reporting period is 59,837[11] - Southwest Synthetic Pharmaceutical Group Co., Ltd. holds 25.82% of the shares, totaling 153,859,360 shares, with 69,607,360 shares frozen[11] - Peking University Health Management Co., Ltd. holds 11.80% of the shares, totaling 70,328,949 shares[11] - The top ten shareholders include several domestic non-state-owned entities, indicating a diverse ownership structure[11] - As of the end of the reporting period, a total of 69,607,360 shares held by Southwest Synthetic Pharmaceutical Group have been judicially frozen, but this will not affect the company's control or daily operations[14] - The company has not reported any significant impact on corporate governance due to the frozen shares[14] Research and Development - Research and development expenses increased by 70.18% to ¥3,805,765.92, indicating a significant rise in investment in R&D activities[9] Regulatory Approvals and Partnerships - The company received approval from the National Medical Products Administration for the drug supplement application for injectable cefotaxime sodium, which passed the consistency evaluation of generic drug quality and efficacy[13] - The company obtained a drug registration certificate for citric acid tamsulosin tablets, confirming compliance with registration requirements[16] - The company is involved in a partnership to establish a private equity investment fund with a target capital contribution of no less than 500 million RMB and no more than 700 million RMB[15] - The company has completed the deregistration of a fund management company due to historical complexities and lack of actual investment activities[15] Liabilities and Retained Earnings - Total liabilities decreased to CNY 1,063,406,151.62 from CNY 1,260,278,114.05, reflecting a decline of 15.6%[21] - The company's retained earnings increased to CNY 547,916,110.01 from CNY 531,210,240.99, a growth of 3.2%[21]